Article Text

other Versions

PDF
Bone status of 5-8 year olds, treated with dexamethasone for chronic lung disease of prematurity
  1. Judith A Eelloo (judith.eelloo{at}cmmc.nhs.uk)
  1. Department of Paediatrics, Saint Mary's Hospital for Women & Children, United Kingdom
    1. Steven A Roberts (steve.roberts{at}manchester.ac.uk)
    1. Biostatistics Group, School of Epidemiology & Health Sciences, Uni of Manchester, United Kingdom
      1. Anthony J. B. Emmerson (anthony.emmerson{at}cmmc.nhs.uk)
      1. Department of Neonatology, St. Mary's Hospital for Women & Children, United Kingdom
        1. Kathryn A Ward (kate.ward{at}manchester.ac.uk)
        1. Clinical Radiology, Imaging Science & Biomed Engineering, Uni of Manchester, United Kingdom
          1. Judith E Adams (judith.adams{at}manchester.ac.uk)
          1. Clinical Radiology, Imaging Science & Biomed Engineering, Uni of Manchester, United Kingdom
            1. M Zulf Mughal (zulf.mughal{at}cmmc.nhs.uk)
            1. Department of Paediatrics, Saint Mary's Hospital for Women & Children, United Kingdom

              Abstract

              Total body bone mineral content and bone mineral apparent density of the lumbar spine were lower in children whose chronic lung disease was treated with dexamethasone (Dx) in the neonatal period, compared to pre-term controls. Therefore, Dx treatment in the neonatal period appears to cause impairment of mineralisation, which persists into childhood.

              • DXA
              • Dexamethasone
              • bone mineral density
              • chronic lung disease of prematurity
              • pQCT

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.